SPAZO2 (SOGUG): Outcomes of patients treated with pazopanib as first line in mRC according to gender in real world

Autor: Jose Carlos Villa Guzman, Rosa Garcia Marrero, José Luis González Larriba, Iciar Garcia Carbonero, Enrique Gallardo Diaz, Javier Luis Puertas Alvarez, Sara Perez Ramirez, Guillermo Velasco, Eva Fernandez Parra, Miguel Angel Climent, Maria Jose Miranda Pallares, José Pablo Maroto Rey, Rocío García Domínguez, Alvaro Pinto, Jose Angel Arranz Arija, Pablo Borrega, Guillermo Crespo, Constanza Maximiano, Cristina Suarez, Andres Meana Garcia
Rok vydání: 2018
Předmět:
Zdroj: Journal of Clinical Oncology. 36:623-623
ISSN: 1527-7755
0732-183X
0309-1465
DOI: 10.1200/jco.2018.36.6_suppl.623
Popis: 623 Background: Treatment of mRC is not affected by gender, studying possible differences in a real-world study, could increase the knowledge of toxicity and possible prognostic factors. Methods: SPAZO2 (NCT03091465) was a retrospective real-world study to analyze the effectiveness of 1st-line pazopanib and subsequent therapies in mRC. Data from 530 pt treated outside CT were collected in 50 spanish centers, and externally monitored. Ineligibility criteria: ECOG > 1, pure nonclear-cell, Hgb < 9 g/dl, renal failure, severe cardiovascular disease, chronic liver disease, or recent neoplasia Results: 530 pt were included, 67.2% men (M), mean age was 66.2 years (26-92). There were no significant differences (M vs W) in the age > 75 (24.7 vs 24.1%), clear cell carcinoma (77.2 vs 79.9%), nephrectomy (72.5 vs 68.4%), IMDC (favourable: 15.2 vs 12.1%, intermediate: 59.3 vs 64.4%, poor: 25.6 vs 23.6%), metastases (lymph nodes: 46.1 vs 43.1%, lung: 69,7 vs 67,2 %, liver: 16 vs 20.1%, bone: 27 vs 24.1%, skin/soft tissues: 1.1 vs 3,4% and CNS: 4,8% vs 6.3%). Discontinuation due to toxicity or comorbidities was 12.4 vs 9.8%. There were no differences in the second lines received (57.9 vs 56.9%), neither response, PFS and OS (table). Median follow up was 39 mo. The gender has no prognostic value when adjusted for the prognostic groups of IMDC (HR of PFS 0.96, CI 95% 0.78-1.2, HR of OS: 0.92, CI 95% 0.72-1.14). Only diarrhea and elevation of uric acid were higher in the men group. Conclusions: Pazopanib was safe and effective in both groups with similar outcome. Women had less diarrhea and less increased uric acid. There were not differences in OS or PFS. In IMDC subgroup analysis, there is a trend towards a better evolution or PFS in the poor prognosis women subgroup. Clinical trial information: NCT03091465. [Table: see text]
Databáze: OpenAIRE
Externí odkaz: